Combining TCTand HC-II HPV to Screen Cervical Lesions and Drug Intervention Methods

Objective 　To approach the screening efficacy of the combination of thinprep cytological test ( TCT) and hybrid capture Ⅱ ( HC-Ⅱ) HPV for cervical lesions and the drug-intervention methods. Methods 　From April 2004 to August 2005, TCT and HC-Ⅱ were applied to screen cervical lesions in 17320 cases. And the pathologic results after cervix biop sies were considered as standard to verify the screening efficiency ; the absorbable and sustained-release fluorouracil ( Fu) medicine membranes were used as intervening treatment to eligible cases. Results 　1754 cases with abnormal results were detected by TCT, and 450 positive samples by HC-Ⅱ HPV. 172 high-risk HPV cases were detected by HC-Ⅱ HPV from 431 cases without infection of HPV proved by TCT. The sensitivity and specificity of screening by TCT or TCT combined with HC-Ⅱ HPV for cervical int raepithelial neoplasia (CIN) II and above are 81. 12 %, 89. 65 % and 72. 08 %, 97. 99 %. After treated with the absorbable and sustained-release Fu medicine membranes, the descending extent of viral loading dose and negative rate and relief rate of 25 CINI cases were obviously superior to control group. The disparity is conspicuous for statistics significance ( P<0. 05) . Conclusion 　The combination of TCT and HC-Ⅱ HPV are able to enhance the specific detection rate of CINII and above. And it is able to decrease the loading dose of HPV or even get rid of it by the absorbable and sustained-release 5-Fu medicine membranes for CINI cases.